E Fund Management Co. Ltd. Takes Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

E Fund Management Co. Ltd. purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,276 shares of the company’s stock, valued at approximately $143,000.

Several other institutional investors and hedge funds have also made changes to their positions in DAWN. R Squared Ltd purchased a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $31,000. Quest Partners LLC increased its stake in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after purchasing an additional 7,668 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $174,000. XTX Topco Ltd acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at $178,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Day One Biopharmaceuticals by 11.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,383 shares of the company’s stock valued at $271,000 after buying an additional 2,180 shares during the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares of the company’s stock, valued at $13,762,739.65. This represents a 2.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 51,064 shares of company stock worth $651,225. Corporate insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $8.67 on Monday. Day One Biopharmaceuticals, Inc. has a 1 year low of $8.02 and a 1 year high of $18.07. The company’s 50 day simple moving average is $11.77 and its 200 day simple moving average is $13.19. The stock has a market capitalization of $878.75 million, a PE ratio of -8.42 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million. As a group, sell-side analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on DAWN shares. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. HC Wainwright reduced their price objective on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and an average price target of $34.57.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.